INOVIO Pharmaceuticals announced on December 12, 2024 that it intends to offer and sell shares of common stock and accompanying warrants in an underwritten public offering2
The offering was priced on December 13, 2024 at a combined public offering price of $3.00 per share of common stock and accompanying warrant1
The offering consisted of 10,000,000 shares of common stock and warrants to purchase 10,000,000 shares at an exercise price of $3.76 per share1
Gross proceeds from the offering were expected to be $30 million before underwriting discounts and commissions1
Oppenheimer & Co. Inc. and Citizens JMP are acting as joint book-running managers, with Stephens Inc. as lead manager1
The offering was expected to close on December 16, 2024, subject to customary closing conditions1
All securities in the offering were being sold by INOVIO itself1
INOVIO is a biotechnology company focused on developing DNA medicines to treat and protect people from HPV-related diseases, cancer, and infectious diseases1
Sources:
1. https://ir.inovio.com/news-releases/news-releases-details/2024/INOVIO-Announces-Pricing-of-30-Million-Public-Offering/default.aspx
2. https://ir.inovio.com/news-releases/news-releases-details/2024/INOVIO-Announces-Proposed-Public-Offering/default.aspx